Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy. (Q36177162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Ramzi G Salloum

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Gail A Jensen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jennifer Elston Lafata

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

26 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

545-549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

The effect on survival of continuing chemotherapy to near death

2 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Bending the Cost Curve in Cancer Care

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Using claims‐based measures to predict performance status score in patients with lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Best supportive care in lung cancer trials is inadequately described: a systematic review

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Treatment of advanced non-small-cell lung cancer in special populations.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Comorbidity and functional status are independent in older cancer patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

Prognostic factors for survival in patients with inoperable lung cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423534

A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly

23 September 2018

1 reference

12 December 2020

Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis

1 reference

12 December 2020

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

12 December 2020

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

12 December 2020

Prevalence of poor performance status in lung cancer patients: implications for research

1 reference

12 December 2020

10.1016/J.LUNGCAN.2012.04.019

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633939%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

PubMed publication ID

22633939

1 reference